soul trial oral semaglutide cardiovascular outcomes 2024 results nejm reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 soul trial oral semaglutide cardiovascular

Some patients may continue treatment long-term to maintain their goal weight while others may discontinue treatment once they achieve their weight loss goals

After an initial decline in HbA1c levels, durability of glycemic control is maintained because of the preservation of -cell function in type 2 diabetes mellitus patients

3 mg dose The starting dose is 3 mg for the first 30 days to help your body get used to the medicine

Theyll tell you when it may be safe for you to start working again based on what you do

Pushed through titration faster than the typical schedule because Id used semaglutide before and knew my body could handle GLP-1 stuff

Conclusion In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies